Kymos and Ipsen form bio molecules R&D unit
Barcelona - South western Europe gets a new R&D unit in the field of biomolecules. Kymos Pharma, a contract researcher based in Barcelona, has signed an agreement with the French biotechnology group Ipsen to create a R&D group in the field of bio molecules and biosimilars. A team of eight scientists from the Ipsen R&D Centre in Sant Feliu de Llobregat (Barcelona) will move into a new immunology laboratory that will be opened in the Barcelona Science Park in early January 2012, conducting regulatory development projects for biotech companies. "Our company will be the only Spanish CRO and one of the few European ones that will be able to offer comprehensive services for biotech companies according to Good Laboratory Practices and Good Manufacturing Practices," says Joan Puig, strategic general manager of Kymos. Ipsen has peldged to assign 20% of its profits to R+D focused on the development of peptides and proteins in the therapeutic areas of neurology, endocrinology, oncology and haematology.